The Food and Drug Administration’s decision to decline approval for MDMA-assisted therapy as a treatment for post-traumatic stress disorder (PTSD) has sent ripples through the burgeoning field of psychedelic medicine. The move deals a blow to the nascent industry, dashing hopes of those who believed the much-anticipated treatment would gain a regulatory green light this year.

Tripping up: The FDA’s decision has raised questions about the future of psychedelic therapies, which have generated significant buzz in recent years. The agency cited insufficient data to allow the use of MDMA, commonly known as ecstasy, and requested that Lykos Therapeutics conduct an additional clinical trial — potentially adding years and millions of dollars to the approval process.

• Lykos said it would appeal the agency’s decision, with CEO Amy Emerson calling it “deeply disappointing” for the millions of Americans with PTSD who haven’t seen new treatment options in over two decades.
• The setback wasn’t entirely unexpected, as an independent expert panel convened by the FDA voted overwhelmingly in June that Lykos had not proven the treatment was effective or that its benefits outweighed the risks.

Despite the FDA’s MDMA decision, some psychedelic stocks have surged in 2024. Shares of Mind MedicineMNMD

have nearly doubled this year, while Atai Life SciencesATAI

was up almost 50% at one point, before going on a downward spiral that sent its stock down over 25% this year.

A Long, Strange Trip Ahead

While the FDA’s decision on MDMA was a setback, some experts believe it will not substantially affect new drug investigations. Companies are working to refine their studies and focus more on the psychotherapeutic component of these novel treatments.

States like Oregon and Colorado have also taken matters into their own hands, recently legalizing psilocybin treatments. The challenges of monetizing psychedelic therapies, securing patent protection, and navigating regulatory hurdles have led some to draw comparisons to the boom and bust of cannabis stocks.

Psychedelic decriminalization and usage has been gaining wider acceptance, but commercial success could still elude drug developers. Concerns remain about drug pricing, insurance coverage, and patient uptake for psychedelic treatments.

Forward-looking: The path forward for psychedelic medicine companies will likely involve refining clinical trial designs, working closely with regulators, and demonstrating the long-term safety and efficacy of their treatments. While an approval of Lykos’s MDMA therapy would have been a watershed moment for the industry, the FDA’s decision serves as a reminder that the journey to mainstream acceptance of psychedelic therapies is far from over.